RET and medullary thyroid gland carcinoma: Therefore, when both RET and RAS mutations are absent in patients with MTC evaluated by companion diagnostic tests using targeted NGS, physicians should consider further comprehensive genomic profiling to identify minor RET alterations and provide potential opportunities for effective treatment.